Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CapsoVision, IncCV · Entity 5974 | Director of Clinical Affairs | August 18, 2025 | August 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CapsoVision, Inc
Report date August 18, 2025 · Filed August 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,834 |
Reported balance
After 2025-08-18 transaction · row 1
1 source rowRow 1 · 2025-08-18 · Exercise / conversion · Acquired 24,834 · Balance 24,834 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2031-10-31 | Direct | 0 |
Reported balance
After 2025-08-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-18 · Exercise / conversion · Disposed 7,507 · Balance 0 F1: These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. F2: The option was granted on October 28, 2021 and is fully vested and exercisable as of the transaction date. F3: There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2032-03-22 | Direct | 3,694 |
Reported balance
After 2025-08-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-18 · Exercise / conversion · Disposed 17,327 · Balance 3,694 F1: These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. F4: The option was granted on March 23, 2022 and is partially vested and exercisable as of the transaction date. F3: There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering.
F2: The option was granted on October 28, 2021 and is fully vested and exercisable as of the transaction date.
F3: There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering.
F4: The option was granted on March 23, 2022 and is partially vested and exercisable as of the transaction date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2025 Filed Aug 22, 2025 20:44 UTC | CapsoVision, Inc CV · Entity 5974 | Exercise / conversionStock Option (right to buy) · Derivative | 17,327 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001378325-25-000014 · wk-form4_1755909887.xml · derivative · entry 3 Petersen Rebecca Ann · CIK 0002075458 · Director of Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,694 Underlying: Common Stock · 17,327 shares Expires 2032-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. F4 · derivative.exercise_date: The option was granted on March 23, 2022 and is partially vested and exercisable as of the transaction date. F3 · derivative.underlying_shares: There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. F3 · balance_after: There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. Read SEC document |
| August 18, 2025 Filed Aug 22, 2025 20:44 UTC | CapsoVision, Inc CV · Entity 5974 | Exercise / conversionStock Option (right to buy) · Derivative | 7,507 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001378325-25-000014 · wk-form4_1755909887.xml · derivative · entry 2 Petersen Rebecca Ann · CIK 0002075458 · Director of Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,507 shares Expires 2031-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. F2 · derivative.exercise_date: The option was granted on October 28, 2021 and is fully vested and exercisable as of the transaction date. F3 · derivative.underlying_shares: There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. F3 · balance_after: There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. Read SEC document |
| August 18, 2025 Filed Aug 22, 2025 20:44 UTC | CapsoVision, Inc CV · Entity 5974 | Exercise / conversionCommon Stock | 24,834 | $0.37 | $9,096.69 |
DisclosureSEC source: 0001378325-25-000014 · wk-form4_1755909887.xml · nonDerivative · entry 1 Petersen Rebecca Ann · CIK 0002075458 · Director of Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.